Press release from Companies
Publicerat: 2021-03-11 17:43:07
Cessatech A/S ("Cessatech" or the "Company") hereby publishes its annual report for the fiscal year 2020. The annual report including the auditor’s report is attached as a pdf. The report is also available on Cessatech’s website www.cessatech.com under ‘Fillings & Reports’.
Full year 2020 (6 April – 31 December): Established the company, the legal entity (6. APR) For more information about Cessatech, please contact: Jes Trygved, CEO Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.
*Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 December 2020 amounted to 3,680,000 shares, the average number of shares during the full-year was 1,537,721. There has been an increase in the number of shares since the completion of the IPO in December 2020. **Solidity: Total equity divided by total capital and liability
Highlights during Q2-2020
Highlights during Q3-2020
Highlights during Q4-2020
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com